# Morning Briefing

Generated: 2026-07-05T23:22:03.944689+00:00
Status: `complete_session_executed_fixture_with_current_projection`
Session: `analyst-2026-07-04`
Dataset: `groundtruth_memory`

## Learned Last Night

- `R001` / `active` / DOI `10.1056/nejme2608684`
  - Evidence: `authority_feed` `10.1056/nejme2608684`
  - Basis: Retraction Watch notice 10.1056/nejme2608684 says original DOI 10.1056/nejmoa2023386 was retracted. Reason: Investigation by Company/Institution;Manipulation of Results;Upgrade/Update of Prior Notice(s);

## Now Contested

- `V2C003::V2C004` / `contested` / DOI `n/a`
  - Evidence: `semantic_inference` `pair:V2C003::V2C004`
  - Basis: Semantic inference for V2C003::V2C004 landed in the contested band (confidence 1.00, direction mutual); basis: Both claims evaluate the effect of marine omega-3 (n-3) fatty acid supplementation on cardiovascular events. Claim A asserts that supplementation lowers the risk for several cardiovascular outcomes (myocardial infarction, coronary heart disease death, cardiovascular disease death, and total cardiovascular disease). Claim B, conversely, states that marine n-3 fatty acid supplementation does not lower the incidence of major cardiovascular events compared with placebo. These are directly contradictory findings regarding the efficacy of marine omega-3 supplementation for cardiovascular disease prevention.

## Revised

- `R001` / `retracted` / DOI `10.1056/nejmoa2023386`
  - Evidence: `authority_feed` `10.1056/nejme2608684`
  - Basis: Retraction Watch record 10.1056/nejme2608684 supersedes original DOI 10.1056/nejmoa2023386; reason: Investigation by Company/Institution;Manipulation of Results;Upgrade/Update of Prior Notice(s);

- `V2C001` / `superseded` / DOI `10.1056/NEJMoa1900906`
  - Evidence: `semantic_inference` `pair:V2C001::V2C002`
  - Basis: Semantic inference for V2C001::V2C002 auto-superseded V2C001 with confidence 0.90; basis: Claim A, a systematic review and meta-analysis published in 2020, synthesizes evidence that Vitamin D supplementation appears to reduce progression to type 2 diabetes in people with prediabetes. Claim B, from a 2019 randomized controlled trial (the D2d study), specifically states that Vitamin D3 supplementation at 4000 IU per day does not significantly lower diabetes risk in adults at high risk. Given that Claim A is a more recent meta-analysis, it likely incorporated the findings of the D2d study (Claim B's source) along with other relevant studies to provide a more comprehensive and statistically robust overall estimate of effect. Therefore, its conclusion, representing a broader synthesis of evidence, supersedes the finding of a single trial, even a large one.

## Purged

- `R001` / `retracted` / DOI `10.1056/nejmoa2023386`
  - Evidence: `authority_feed` `10.1056/nejme2608684`
  - Basis: Retraction Watch record 10.1056/nejme2608684 supersedes original DOI 10.1056/nejmoa2023386; reason: Investigation by Company/Institution;Manipulation of Results;Upgrade/Update of Prior Notice(s);

## Before Answer

Question: `What does the memory say about Avacopan for the Treatment of ANCA-Associated Vasculitis?`

```text
groundtruth_memory still cites the active claim 10.1056/nejmoa2023386 from NEJM: The New England Journal of Medicine: The paper claimed that avacopan for the Treatment of ANCA-Associated Vasculitis.
```

## After Answer

```text
groundtruth_memory no longer cites original DOI 10.1056/nejmoa2023386. The belief is retracted by authority_feed evidence 10.1056/nejme2608684: Investigation by Company/Institution;Manipulation of Results;Upgrade/Update of Prior Notice(s);
```